March 01, 2017
Weil advised Eli Lilly and Company, a global healthcare leader, in its $960 million acquisition of CoLucid Pharmaceuticals, Inc., a public biopharmaceutical company developing lasmiditan oral tablets for the acute treatment of migraine headaches. This all-cash transaction enhanced Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline. The transaction closed March 01, 2017.
The Weil team that advised Eli Lilly was led by Mergers & Acquisitions partners Raymond Gietz and Matthew Gilroy and included Technology & IP Transactions partner Jeffrey Osterman; Tax partner Helyn Goldstein; Executive Compensation & Benefits partner Amy Rubin; Environmental counsel John O’Loughlin; Mergers & Acquisitions associates Christopher Moore, Christina De Vuono, Andrea Ryken and Stephen Liebscher; Technology & IP Transactions associates Jennifer Yoon and Jasmine Woodard Rose; Tax associate Joseph Reich; Executive Compensation & Benefits associates Amanda Rosenblum and Franny Glick.